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Abstract 
Background: Relative telomere length in peripheral blood leukocytes has been evaluated as a 
potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting 
findings.  
Objective: We performed an analysis of genetic variants associated with leukocyte telomere 
length to assess the relationship between telomere length and RCC risk using Mendelian 
randomization, an approach unaffected by biases from temporal variability and reverse causation 
that might have affected earlier investigations. 
Design, Setting, and Participants: Genotypes from nine telomere length associated variants for 
10,784 cases and 20,406 cancer-free controls from six genome-wide association studies (GWAS) 
of RCC were aggregated into a weighted genetic risk score (GRS) predictive of leukocyte 
telomere length.  
Outcome Measurements and Statistical Analysis: Odds ratios (ORs) relating the GRS and RCC 
risk were computed in individual GWAS datasets and combined by meta-analysis. 
Results and Limitations: Longer genetically inferred telomere length was associated with an 
increased risk of RCC (OR=2.07 per predicted kilobase increase, 95% CI=1.70-2.53; P<0.0001). 
As a sensitivity analysis, we excluded two telomere length variants in linkage disequilibrium 
(R
2
>0.5) with GWAS-identified RCC risk variants (rs10936599 and rs9420907) from the 
telomere length GRS; despite this exclusion, a statistically significant association between the 
GRS and RCC risk persisted (OR=1.73, 95% CI=1.36-2.21, P<0.0001). Exploratory analyses for 
individual histologic subtypes suggested comparable associations with the telomere length GRS 
for clear cell (N=5,573; OR=1.93, 95% CI=1.50-2.49, P<0.0001), papillary (N=573; OR=1.96, 
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95% CI=1.01-3.81, P=0.046) and chromophobe RCC (N=203; OR=2.37, 95% CI=0.78-7.17, 
P=0.13).  
Conclusions: Our investigation adds to the growing body of evidence indicating some aspect of 
longer telomere length is important for RCC risk. 
Patient Summary: Telomeres are segments of DNA at chromosome ends that maintain 
chromosomal stability. Our study investigated the relationship between genetic variants 
associated with telomere length and RCC risk. We found evidence suggesting individuals with 
inherited predisposition to longer telomere length are at increased risk of developing RCC.  
  
5 
Introduction 
Telomeres are TTAGGG nucleotide repeats and a protein complex at chromosome ends 
that play an essential role in maintaining chromosomal stability. Due to the inability of DNA 
polymerase to fully extend 3’ DNA ends, telomeres become gradually shorter with each cell 
division in the absence of telomerase activity[1]. Although in normal cells critically short 
telomeres will trigger cellular senescence and death, cancer cells can continue to divide despite 
telomere shortening and the resultant genomic instability[2]. Alternatively, upregulated 
telomerase activity leading to increased telomere length may also promote tumorigenesis by 
conferring properties of immortal growth[3]. Indeed, recent studies suggest longer telomere 
length may be a risk factor for select tumor types including melanoma, lung cancer, chronic 
lymphocytic leukemia, glioma and ovarian cancer[4-7]. 
As such, relative telomere length in peripheral blood leukocytes has been evaluated in 
numerous population-based studies as a suspected marker of cancer risk[8]. Most of these studies 
have characterized telomere length using multiplex quantitative polymerase chain reaction 
(qPCR) assays[9]. Results of studies of leukocyte telomere length and risk of renal cell 
carcinoma (RCC) have been inconsistent. Two small hospital-based case-control studies reported 
inverse associations between telomere length and risk of RCC[10, 11], whereas no significant 
evidence of an association was observed in a larger population-based case-control study[12] and 
two cohort-based investigations using pre-diagnostic samples[13, 14]. In contrast, longer 
leukocyte telomere length has been associated with reduced RCC survival[15]. Telomerase 
activity is elevated in renal tumors compared to adjacent normal renal tissue and has been 
associated with clinicopathologic features of advanced disease[16, 17].  
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These previous studies have several limitations. Leukocyte telomere length 
measurements in case-control studies, using post-diagnosis blood samples, may have been 
influenced by effects of the disease. All studies measured telomere length from a single time 
point, which may not adequately reflect telomere length status in the etiologically relevant time 
window, and were susceptible to confounding from RCC risk factors that may be associated with 
telomere length such as smoking[13, 18] and obesity[19]. Furthermore, qPCR-based 
measurements of telomere length are sensitive to pre-analytic factors such as DNA source 
material and extraction method[12, 20, 21].  
Nine common genetic variants have been identified in genome-wide association studies 
(GWAS) that are associated with leukocyte telomere length at a level of genome-wide 
significance (P<5×10
−8
)[22-24]. Recent studies have evaluated the relationship between these 
genetic proxies of telomere length and risk of cancer and found evidence suggesting longer 
genetically inferred telomere length is associated with increased cancer risk[4-7]. The approach 
employed by these studies, Mendelian randomization, uses genetic variants associated with 
leukocyte telomere length as genetic instruments to investigate the relationship between 
leukocyte telomere length and RCC risk. For resulting effect estimates to have a valid causal 
interpretation, several conditions must hold: (1) the telomere length associated variants must be 
associated with telomere length in circulating leukocytes, (2) the telomere length associated 
variants should not be associated with other factors that are associated with telomere length and 
RCC risk and (3) the telomere length associated variants can only influence RCC risk by their 
effect on telomere length, that is they cannot have pleiotropic effects. An advantage of this 
approach is that it is not susceptible to the biases associated with measured telomere length as 
described above. A recent investigation surveying several chronic conditions suggested a 
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marginal positive association (P=0.01) between genetically predicted telomere length and RCC 
risk, although the sample size was smaller (N=2,461 RCC cases)[7]. 
In the present study, we evaluated RCC risk in relation to individual telomere length-
related genetic variants and an aggregate genetic risk score (GRS) of telomere length associated 
genetic variants in a large sample of six RCC GWAS datasets combined by meta-analysis to 
investigate a potential etiologic relationship between telomere length and RCC risk. We 
evaluated whether a genetic profile that is associated with longer telomere length is associated 
with risk of overall RCC and RCC subtypes, and investigated potential modifiers of this 
relationship.  
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Material and Methods 
The RCC GWAS meta-analysis included a total of 10,784 RCC cases and 20,406 
controls of European ancestry from six independent scans conducted at the International Agency 
for Cancer Research (IARC) (two scans totaling 5,219 RCC cases and 8,011 cancer-free 
controls; analyzed as a combined dataset), the MD Anderson Cancer Center (MDA) (893 RCC 
cases, 556 cancer-free controls), the U.S. National Cancer Institute (NCI-1: 1,311 RCC cases, 
3,424 cancer-free controls; NCI-2: 2,417 RCC cases, 4,391 cancer-free controls; analyzed 
separately) and the Institute of Cancer Research (UK) (944 RCC cases, 4,024 cancer-free 
controls)[25]. Cases were restricted to adults diagnosed with RCC, defined on the basis of the 
International Classification of Disease for Oncology 2nd and 3rd Edition topography code C64. 
Samples were genotyped on commercially available Illumina SNP microarrays (HumanHap 300, 
HumanHap 500, HumanHap 610, HumanHap 660w, HumanHap 1.2M, OmniExpress, Omni5M) 
after standard quality control metrics. High-quality genotypes were phased and imputation was 
performed using either MaCH (IARC) or IMPUTE2 (UK, NCI1, NCI2 and UK) with 1000 
Genomes Project (Phase 1, Version 3) samples used as a reference panel for imputing missing 
genotypes. Protocols for studies participating in each GWAS were reviewed by the Institutional 
Review Boards of their respective institutions. All participants provided written informed 
consent. Further details on study design and methods have been previously reported[25]. 
 For each study participant, genotypes were extracted for nine previously identified 
common single nucleotide polymorphisms (SNPs) associated with telomere length in circulating 
leukocytes (rs10936599, rs11125529, rs2736100, rs3027234, rs6772228, rs755017, rs7675998, 
rs8105767 and rs9420907). Telomere length associated SNPs not directly genotyped were 
extracted from imputed data for each scan (Supplementary Table 1)[25].  
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 Risk of RCC was evaluated in relation to each of the nine telomere length associated 
variants. Association testing was conducted separately for each contributing dataset assuming a 
log-additive (trend) for the effect of the telomere length associated variants on RCC risk. 
Covariate adjustment differed by dataset and are as follows: 19 significant eigenvectors for 
IARC, age and two significant eigenvectors for MDA, study indicator variables for NCI1, sex 
and 3 significant eigenvectors for NCI2, and no covariate adjustment for the UK study. RCC 
association results for telomere length associated variants from each dataset were combined by 
meta-analysis using a fixed effects model. Cochran’s Q tests for heterogeneity were conducted to 
identify a lack of consistency across studies. 
 A GRS was calculated for the nine telomere length associated variants as follows: 
GRS𝑖 =∑𝑤𝑗𝑥𝑖𝑗
9
𝑗=1
 
where GRSi is the risk score for individual i, xij is the number of telomere length increasing 
alleles for the jth telomere length associated variant and wj is the weight or effect coefficient for 
each telomere length associated variant. A higher GRS value for an individual indicates longer 
genetically inferred telomere length. Previously published telomere length associated effect 
estimates ( values) scaled to estimated kilobases of telomere length per length increasing allele 
were used for wj[22-24]. GRS association tests were conducted separately for each contributing 
study using the same covariates as the single SNP association tests previously described. Results 
from each study were merged by fixed effects meta-analysis and heterogeneity tests were 
conducted to detect potential departures from homogeneity. Additionally, sub-analyses by RCC 
subtype as well as analyses stratified by sex, body mass index (BMI), history of hypertension 
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and smoking status were conducted to comprehensively assess the relationship between telomere 
length associated variants and RCC risk. 
 In addition to the GRS analysis, summary statistics from the nine telomere length 
associated variants were also combined in analyses using an inverse variance weighting method 
and a likelihood-based method[26]. Both methods use average summary association estimates 
for the telomere length associated variants with RCC risk to estimate the overall effect of 
telomere length on RCC risk. These methods produce similar estimates and precision as 
individual-level data, but have the advantage of using effect statistics from different studies. An 
online web tool by Burgess et al.[26] accessed at https://sb452.shinyapps.io/summarized/ on 
February 10, 2017 was used to calculate the inverse variance and likelihood-based estimates. 
Tests of heterogeneity were performed to assess if a telomere length associated variant’s effect 
on RCC is proportional to its effect on telomere length. Additionally, MR-Egger regression 
models were fit to evaluate the potential for pleiotropic effects of variants[27]. 
 Unless otherwise stated, statistical analyses and plotting were performed on a 64-bit build 
of R version 3.3.0 “Supposedly Educational”. Meta-analyses were performed using the R 
package metafor and Egger regression[27] was performed using the R package 
MendelianRandomization. All statistical tests were two-sided with P values less than 0.05 
considered significant.  
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Results 
 Associations between the telomere length associated variants and RCC risk are reported 
in Table 1 and Supplementary Figure 1. Of the nine telomere length associated variants, five 
variants (rs10936599, rs2736100, rs9420907, rs8105767 and rs6772228) displayed evidence for 
an individual association with RCC risk (P<0.05) and three (rs10936599, rs2736100, rs9420907) 
were associated at Bonferroni corrected levels (P<0.006). This is substantially more than the 
number of telomere length variants associated with RCC risk that would be expected by chance 
(exact binomial P<0.0001). For all the telomere length-related variants associated with RCC, the 
allele related to longer telomere length was associated with an increased risk of RCC. There was 
no evidence for heterogeneity in effect estimates across studies. 
We observed a highly statistically significant association between the telomere length 
GRS and RCC risk (OR=2.07 per predicted kilobase increase, 95% CI=1.70-2.53, P<0.0001, 
Figure 1), indicating longer genetically inferred telomere length is associated with increased 
RCC risk. In an analysis of GRS deciles, a generally monotonic trend across deciles was 
observed (Figure 2). After removing two telomere length variants from the GRS that were in 
linkage disequilibrium (LD) with RCC susceptibility loci reported in the RCC GWAS 
(rs10936599 in LD with rs10936602, and rs9420907 in LD with rs11813268; R
2
 0.59 and 0.76 in 
the CEU 1000 Genomes population, respectively[28, 29]), the reduced GRS effect estimate was 
attenuated but remained statistically significant (OR=1.73 per predicted kilobase increase, 95% 
CI=1.36-2.21, P<0.0001, Supplementary Figure 2). 
A similar direct relationship between telomere length associated genetic variants and 
RCC risk was observed when applying summary statistic based approaches to our RCC cases 
and controls. The likelihood-based pooled estimate for a predicted kilobase increase in telomere 
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length is a 2.00 increase in the odds of developing RCC (95% CI=1.64-2.43, P<0.0001, Figure 
3). Likewise, the inverse variance weighted method gave a similar effect estimate (OR=1.96, 
95% CI=1.63-2.35, P<0.0001). There was no significant heterogeneity when comparing the ratio 
of effect sizes of the genetic variants on telomere length to the effect sizes of the genetic variants 
on RCC risk (P=0.08). Furthermore, results from MR-Egger regression estimated an intercept of 
-0.043 (95% CI=-0.133 0.047, P=0.4), suggesting no significant evidence for directional 
pleiotropy (Supplementary Figure 3). 
 In analyses restricted to individual histologic subtypes, comparable associations were 
observed for each of the telomere length associated variants across RCC subtype 
(Supplementary Table 2). Likewise, similar telomere length associated GRS associations were 
observed for clear cell RCC (OR=1.93 per predicted kilobase increase, 95% CI=1.50-2.49, 
P<0.0001, Supplementary Figure 4), papillary RCC (OR=1.96, 95% CI=1.01-3.81, P=0.046, 
Supplementary Figure 5) and chromophobe RCC (OR=2.37, 95% CI=0.78-7.17, P=0.13, 
Supplementary Figure 6), although the latter finding did not reach statistical significance. 
Analyses conducted across strata of sex, BMI, history of hypertension and smoking status did not 
identify statistically significant evidence of effect modification by these factors (Supplementary 
Figures 7–10). 
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Discussion 
Our findings suggest that an excess of telomere length-related variants is associated with 
RCC risk and, in aggregate, a genetic risk score predicting longer telomere length in peripheral 
blood leukocytes is strongly associated with increased RCC risk. The association between longer 
genetically-predicted telomere length and RCC risk remained statistically significant even after 
removing two telomere length associated variants highly correlated with GWAS-identified RCC 
risk variants from the telomere length GRS, indicating additional telomere length associated 
SNPs are associated with RCC risk beyond these two potentially influential SNPs. We observed 
no significant differences in the overall telomere length GRS and RCC association across 
common RCC subtypes, although our power to detect heterogeneity in associations across 
subtypes was limited. Future studies with larger collections of chromophobe and papillary RCC 
cases are needed to confirm these associations with telomere length variants by subtype. 
 With 10,784 RCC cases and 20,406 cancer-free controls, this study is the largest to date 
to assess the relationship between telomere length and RCC risk. Rather than directly measuring 
leukocyte telomere length, our study used genetic variants highly associated with leukocyte 
telomere length as a surrogate of telomere length to assess the relationship with RCC risk. Our 
genetic approach has several advantages; it is not susceptible to potential biases due to the timing 
of specimen collection in relation to diagnosis, potential confounding, or differences in pre-
analytical specimen processing.  
While many lines of evidence in our analysis suggest a clear and robust association 
between longer telomere length and RCC risk, perhaps the main limitation of our approach is in 
estimating the magnitude of this association. The telomere length associated variants used in this 
analysis originated from GWAS studies of leukocyte telomere length, where telomere length was 
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measured by qPCR[22-24]. These studies then use correlations between qPCR measured 
telomere length and Southern blot from other laboratories to extrapolate the base pair change in 
telomere length associated with each variant allele. While these conversions might not be 
entirely accurate, we chose to use kilobase change in telomere length as weights in our telomere 
length GRS to facilitate combining variants discovered in different studies into a homogenous 
telomere length GRS. As such, measurement error may be present in the reported effect 
estimates; however, the association P values remain valid.  
Renal epithelial cell telomere length would perhaps be the best means to assess the 
relationship between telomere length and RCC risk. Ideally, genetic surrogates of renal epithelial 
cell telomere length would be available as instruments in our current analysis, but as of 
publication no genetic variants have been reported to be associated with renal cell telomere 
length. A prior study has demonstrated that telomere length measurements in leukocytes and 
non-malignant renal tissue are correlated, with a Pearson correlation coefficient of 0.44[30]. This 
relationship between leukocyte telomere length and renal cell telomere length suggests the most 
likely biological mechanism linking increased leukocyte telomere length to RCC risk may be 
longer correlated renal epithelial cell telomere length. Longer renal telomere length may promote 
renal tumor growth by increasing replicative potential of renal epithelial cells, although further 
studies are needed to confirm this hypothesis and alternative explanations are possible. If 
validated, our findings indicating longer telomere length as a risk factor for RCC may inform 
clinicians of potential RCC risks associated with administering prolonged treatments with 
telomerase activating properties (e.g. androgen therapy[31]), particularly in high-risk RCC 
populations. Additionally, telomere length GRSs, in combination with other genetic, clinical and 
risk factor data, may hold future clinical value for the development and application of RCC risk 
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prediction models in support of a “precision prevention” paradigm of targeted disease 
prevention. 
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Conclusions 
Our investigation adds to the growing body of evidence indicating some aspect of 
telomere length is important for the development of a variety of common cancer types suggesting 
clinicians weigh the potential increases in cancer risk when considering treatments with 
telomerase activating properties. Future studies are needed to decipher which components of 
telomere biology, whether it be telomere length, telomerase activity or an altogether unknown 
mechanism, are biologically important in oncogenesis. Such mechanistic insight will lead to 
improved risk modeling and identify potentially promising targets for drug development. 
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Table and Figure Legends 
Table 1. Associations of telomere length associated variants with RCC risk. 
 
Figure 1. Forest plot for associations of the telomere length associated GRS with RCC risk. 
Odds ratios are scaled to predicted kilobase increase in telomere length. Combined association 
P<0.0001. Heterogeneity P=0.96. 
 
Figure 2. Associations of telomere length GRS decile with RCC. Dashed line represents the 
baseline for the reference decile (lowest decile). Error bars represent 95% confidence intervals 
around the odds ratio association for each GRS decile and RCC. 
 
Figure 3. The effect of each variant on telomere length and RCC risk. Estimates for the SNP--
telomere and SNP--RCC associations are presented in Table 1. Error bars around each estimate 
are 95% confidence intervals around the β estimate. A best fit regression line (dashed line) and 
95% confidence interval (shaded region) are plotted using the likelihood based estimate 
(OR=2.00, 95% CI=1.64-2.43, P<0.0001). 
 
Supplementary Tables 
Supplementary Table 1. Minimac R2 (IARC) or IMPUTE2 info scores (MDA, NCI1, NCI2, UK) for imputed variants.  
 
  rs11125529 rs6772228 rs10936599 rs7675998 rs2736100 rs9420907 rs3027234 rs8105767 rs755017 
IARC 1.00 0.70 Genotyped 0.99 Genotyped Genotyped 0.99 0.95 1.00 
MDA 1.00 0.84 Genotyped 1.00 Genotyped Genotyped 1.00 1.00 1.00 
NCI1 1.00 0.83 Genotyped 1.00 Genotyped Genotyped 1.00 1.00 1.00 
NCI2 1.00 0.81 Genotyped 1.00 Genotyped 1.00 1.00 1.00 Genotyped 
UK 1.00 0.85 Genotyped 1.00 Genotyped 0.99 1.00 1.00 Genotyped 
 
Variants that were directly genotyped are denoted as “Genotyped”. Differences in which variants were imputed and genotyped 
across studies reflects differences in array coverage for commercially available Illumina genotyping platforms used by the studies. 
 
  
Supplementary Table 2. Telomere length associated variant associations with each major RCC subtype and RCC overall. 
 
 
Variant 
Alleles Clear Cell RCC Chromophobe RCC Papillary RCC RCC Overall 
Short Long OR LCL UCL OR LCL UCL OR LCL UCL OR LCL UCL 
rs10936599 T C 1.126 1.063 1.192 1.055 0.830 1.341 1.015 0.878 1.172 1.105 1.059 1.154 
rs2736100 A C 1.091 1.040 1.144 1.040 0.848 1.274 1.161 1.025 1.315 1.070 1.032 1.110 
rs7675998 A G 0.976 0.921 1.033 1.163 0.908 1.489 0.976 0.843 1.131 1.013 0.969 1.059 
rs9420907 A C 1.148 1.074 1.227 1.154 0.879 1.517 1.242 1.053 1.465 1.124 1.067 1.183 
rs8105767 A G 1.002 0.951 1.057 0.982 0.785 1.228 1.013 0.884 1.160 1.049 1.007 1.092 
rs755017 A G 1.030 0.956 1.109 1.290 0.967 1.720 1.080 0.898 1.298 1.012 0.956 1.071 
rs11125529 C A 1.041 0.971 1.116 1.071 0.799 1.436 0.953 0.794 1.145 1.014 0.962 1.070 
rs6772228 A T 1.062 0.938 1.202 0.801 0.485 1.324 1.159 0.836 1.608 1.127 1.026 1.239 
rs3027234 T C 0.975 0.920 1.034 1.000 0.780 1.281 0.899 0.776 1.042 1.016 0.972 1.063 
 
OR=odds ratio; LCL=lower 95% confidence interval; UCL=upper 95% confidence interval 
 
Supplementary Figures 
Supplementary Figure 1. Forest plots for associations of each telomere length associated 
variant with RCC risk. 
 
     
 
     
 
     
  
Supplementary Figure 2. Forest plot for RCC association of the telomere length associated GRS 
that removes rs10936599—TERC and rs9420907—OBFC1 GWAS variants. 
 
  
Supplementary Figure 3. Comparison of Egger regression effect estimates (dashed lines) to 
standard (dotted lines) and IVW based estimation approaches. Egger regression estimated an 
intercept of -0.043 (95% CI=-0.133-0.047, P-value=0.352) and an estimated odds ratio of 3.20 
(95% CI=1.10-9.27, P-value=0.03). 
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Supplementary Figure 4. Forest plot for associations of the telomere length associated GRS 
with clear cell RCC risk. 
 
 
 
  
Supplementary Figure 5. Forest plot for associations of the telomere length associated GRS 
with papillary RCC risk. 
 
 
 
  
Supplementary Figure 6. Forest plot for associations of the telomere length associated GRS 
with chromophobe RCC risk. 
 
 
  
Supplementary Figure 7. Forest plot for associations of telomere length associated GRS with 
RCC by strata of sex. 
 
 
  
Supplementary Figure 8. Forest plot for associations of telomere length associated GRS with 
RCC by strata of BMI. 
 
 
 
  
Supplementary Figure 9. Forest plot for associations of telomere length associated GRS with 
RCC by strata of hypertension. 
 
 
 
  
Supplementary Figure 10. Forest plot for associations of telomere length associated GRS with 
RCC by strata of smoking. 
 
 
